—
Summary‘Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2016’, provides an overview of the Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) and features dormant and discontinued projects.
Request a sample report @ https://www.wiseguyreports.com/sample-request/693291-leber-s-hereditary-optic-review-h2-2016
Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy)
- The report reviews pipeline therapeutics for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) therapeutics and enlists all their major and minor projects
- The report assesses Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/693291-leber-s-hereditary-optic-review-h2-2016
Key points in table of content
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Report Coverage 6
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Overview 7
Therapeutics Development 8
Pipeline Products for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Overview 8
Pipeline Products for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Comparative Analysis 9
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Therapeutics under Development by Companies 10
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Therapeutics under Investigation by Universities/Institutes 11
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Products under Development by Companies 16
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Products under Investigation by Universities/Institutes 17
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Companies Involved in Therapeutics Development 18
Alkeus Pharmaceuticals, Inc. 18
Biovista Inc. 19
GenSight Biologics S.A. 20
Ixchel Pharma, LLC 21
Khondrion BV 22
Spark Therapeutics, Inc. 23
Stealth BioTherapeutics Inc. 24
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
BVA-202 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
BVA-203 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Drug for Lebers Hereditary Optic Neuropathy - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
elamipretide - Drug Profile 37
Product Description 37
Mechanism Of Action 37
Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=693291
Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WiseGuy Research Consultant Pvt Ltd
Address: WISE GUY RESEARCH CONSULTANTS PVT LTD Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India Ph: +91 841 198 5042 info@wiseguyreports.com
Phone: +1-646-845-9349 (US) +44 208 133 9349 (UK)t
Website: https://www.wiseguyreports.com
Release ID: 140070